Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,...
Patent
1996-06-21
1998-07-21
Caputa, Anthony C.
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
4241331, 4241411, 4241451, 435 71, 5303881, 53038823, A61K 39395, A61K 3940, G01N 3353, C07K 1600
Patent
active
057831840
ABSTRACT:
The present invention relates to treatment and diagnosis of conditions mediated by IL-5 and excess eosinophil production, and more specifically to mAbs and other altered antibodies such as Fabs, chimeric, human and humanized antibodies that do not block binding of human IL-5 to the .alpha.-chain of the human IL-5 receptor.
REFERENCES:
patent: 4980359 (1990-12-01), Hasspacker et al.
patent: 5455337 (1995-10-01), Devos et al.
Morrison et al (PNAS USA vol. 81 Nov. 1984 pp. 6851-6855).
McNamee et al (J. of Immunological Methods vol. 141 (1991) pp. 81-88).
Dickason, et al., "Delineation of IL-5 Domains Predicted to Engage the IL-5 Receptor Complex", J. Immunol., 156, pp. 1030-1037 (1996).
Dickason, et al., "Enhanced Detection of Human IL-5 In Biological Fluids Utilizing Murine Monoclonal Antibodies Which Delineate Distinct Neutralizing Epitopes", Cytokine, 6, pp. 647-656 (1994).
Cornelis, S., "Detailed analysis of the IL-5-IL-5R.alpha. interaction: characterization of crucial residues on the ligand and the receptor", The EMBO Journal, 14 pp. 3395-3402 (1995).
Tavernier, J., "Identification of receptor-binding domains on human interleukin 5 and design of an interleukin 5-derived receptor antagonist", Proc. Natl. Acad. Sci. USA, 92, pp. 5194-5198 (1995).
Graber, P., "Identification of Key Charged Residues of Human Interleukin-5 in Receptor Binding and Cellular Activation", The Journal of Biological Chemistry., 270, pp. 15762-15769 (1995).
Migita, M., "Characterization of the human IL-5 receptors on eosinophils", Cellular Immunology., 133, pp. 484-497 (1991).
Rolink, A., "Monoclonal Antibodies Reactive With the Mouse Interleukin 5 Receptor", J. Exp. Med., 169, 1693-1701 (1989).
Murata, Y., "Molecular Cloning and Expression of the Human Interleukin 5 Receptor", J. Exp. Med., 175, pp. 341-351 (1992).
Tavernier, J., "Molecular basis of the membrane-anchored and two soluble isoforms of the human interleukin 5 receptor .alpha. subunit", Proc. Natl. Sci. USA, 89, pp. 7041-7045 (1992).
Abrams, J., Eosinophil-active aytokines in human disease: development and use of monoclonal antibodies to IL3, IL5, and GM-CSF Eosinophilis in Allergy and Inflammation, pp. 133-157 (1994).
Banks, M., "Soluble Iterleukin 5 Receptor .alpha.-Chain Binding Assays: Use for Screening and Analysis of Interleukin-5 Mutants", Analytical Biochemistry, 230, pp. 321-328 (1995).
Johanson, K., "Binding Interactions of Human Interleukin 5 with its Receptor .alpha. Subunit", The Journal of Biological Chemistry, 270, pp. 9459-9471 (1995).
Appelbaum Edward Robert
Cook Richard Murray
Caputa Anthony C.
Eagle Alissa M.
King William T.
Lentz Edward T.
Navarro Mark
LandOfFree
Method for treatment and diagnosis of IL-5 mediated disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for treatment and diagnosis of IL-5 mediated disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for treatment and diagnosis of IL-5 mediated disorders will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1644284